

Title Page

Title of the Manuscript: Effects of Inhaled Aromatherapy on Sleep Quality and Cognitive Function in Older Adults: A Randomized Controlled Trial

Short Title: Inhaled Aromatherapy in Older Adults

Authors:

Belçim Ede Sarıkaya, PhD¹ (ORCID: 0000-0001-8701-658X)

Sebahat Ateş, PhD² (ORCID: 0000-0002-8300-8037)

Tuğba Kaman, PhD³ (ORCID: 0000-0002-5885-0193)

Ayşe Arzu Sayın Şakul, PhD⁴ (ORCID: 0000-0002-9354-0000)

Affiliations:

¹ Istanbul Kent University, Faculty of Health Sciences, Department of Nursing, Istanbul, Türkiye

² Istanbul Bilgi University, Faculty of Health Sciences, Department of Nursing, Istanbul, Türkiye

³ Üsküdar University, Vocational School of Health Services / Institute of Health Sciences, Medicinal and Aromatic Plants Programme, Istanbul, Türkiye

⁴ Istanbul Medipol University, Faculty of Medicine, Department of Internal Medicine, Division of Medical Pharmacology, Istanbul, Türkiye

Corresponding Author:

Assoc. Prof. Dr. Sebahat Ateş

Istanbul Bilgi University Faculty of Health Sciences, Department of Nursing, Pir Hüsametdin

Street No. 20, Hacıahmet Neighborhood, 34440 Beyoğlu, Istanbul, Türkiye

Email: sebahat.ates@bilgi.edu.tr

Phone: +90 533 764 76 04

Manuscript Details:

© The Author(s) 2026. Published by Oxford University Press on behalf of the Gerontological Society of America. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

1
2
3 Word count (title page, main text and abstract): 5914
4

5 **Number of data elements (main text):** Tables: 5; Figures: 1
6

7
8 eTable 1; eFigure1; eFigure 2
9

10
11
12 **Abstract**
13

14 **Background**
15

16 Sleep disturbances and cognitive decline frequently coexist in older adults and are associated
17 with adverse health outcomes. Aromatherapy has emerged as a potential non-pharmacological
18 intervention; however, evidence from inhalation-based protocols integrating both subjective
19 and objective sleep assessments remains limited.
20
21
22
23
24
25

26 **Methods**
27

28 This single-blind, randomised controlled trial was conducted in a residential care facility in
29 Istanbul between January and June 2024. Sixty participants aged ≥ 65 years were randomly
30 allocated to an intervention group (n=30) or a control group (n=30). The intervention consisted
31 of inhaling a peppermint–palmarosa blend in the morning and a nighttime blend of vetiver,
32 cedarwood, clary sage, petitgrain, and grapefruit oils for 10 minutes daily over 30 days.
33 Outcomes included the Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, and Blessed
34 Orientation–Memory–Concentration Test, alongside objective sleep parameters obtained from
35 Oppo Watch Free wearable smartwatches using photoplethysmography and accelerometer-
36 based algorithms.
37
38
39
40
41
42
43
44
45
46
47
48
49

50 **Results**
51

52 Compared with the control group, the intervention group demonstrated significant
53 improvements in total sleep time (d=1.29), REM sleep duration (d=1.34), and deep sleep (N3)
54 duration (d=1.47), along with reduced sleep latency (d=-1.12) (all $p < 0.001$). Daytime
55 sleepiness decreased, and subjective sleep quality improved. Cognitive performance also
56
57
58
59
60

1
2
3 improved, with significant gains observed in orientation, memory, and concentration, whereas
4
5 no significant changes were observed in the control group.
6
7

8 **Conclusions**

9
10 A circadian-aligned, multi-component inhalation aromatherapy protocol may represent a
11
12 feasible and clinically relevant complementary intervention to improve sleep architecture and
13
14 cognitive outcomes in older adults residing in residential care settings.
15
16

17
18 **Keywords:** olfactory stimulation; essential oils; sleep architecture; wearable sleep tracking;
19
20 residential care
21
22

23 **Trial Registration:**

24
25
26 ClinicalTrials.gov: NCT06208800.
27
28

29 **1. Introduction (Background)**

30
31
32 Global demographic trends indicate a substantial increase in the ageing population, leading to
33
34 profound transformations in health, economic, and social systems worldwide. Declining
35
36 fertility rates, extended life expectancy, and advances in healthcare services have accelerated
37
38 population ageing across societies. According to data from the Turkish Statistical Institute (1),
39
40 the proportion of individuals aged 65 years and above was 9.7% in 2021 and is projected to
41
42 reach 25.6% by 2080. Similarly, the World Health Organization (2) estimates that by 2050, one
43
44 in every six people globally will be aged 65 years or older. This demographic shift underscores
45
46 the need for early identification of health problems in older adults and the development of
47
48 specialised geriatric care services.
49
50
51

52
53
54 Sleep disorders are among the most common yet frequently overlooked health problems in older
55
56 adults. Physiological, psychosocial, and neuroendocrine changes associated with ageing lead to
57
58 substantial alterations in sleep architecture. Evidence indicates that older adults experience
59
60

1
2
3 decreases in total sleep time, sleep efficiency, and REM sleep duration, along with prolonged
4 sleep latency and frequent nocturnal awakenings (3,4). Objective sleep assessments further
5 show that older adults spend more time in light sleep stages (NREM 1–2), whereas deep sleep
6 (NREM 3) and REM stages are markedly reduced (5). More than half of community-dwelling
7 older adults report at least one chronic sleep disturbance (6).
8
9

10
11
12
13
14
15 The aetiology of sleep problems in older adults is multifactorial. Chronic diseases such as
16 cardiovascular disorders, arthritis, pulmonary diseases, gastroesophageal reflux, persistent pain,
17 depression, anxiety, and the widespread use of multiple medications negatively affect sleep
18 quality (7,8). Age-related reductions in melatonin and growth hormone secretion, as well as
19 alterations in cortisol and thyrotropin (TSH) rhythms, further impair sleep continuity, leading
20 to fragmented, non-restorative sleep (9). Poor-quality sleep increases the risk of falls,
21 depression, frailty, and cognitive impairment, and predisposes older adults to neuropsychiatric
22 complications, including attention deficits, disorientation, and delirium (10,11). Furthermore,
23 inadequate sleep negatively affects memory consolidation and neuroplasticity (12,13).
24
25
26
27
28
29
30
31
32
33
34
35

36
37 Structural brain changes accompanying ageing—particularly volume reductions in the
38 hippocampus and prefrontal cortex—contribute to impairments in memory, attention, and
39 executive functioning (14,15). According to WHO data (2), the number of individuals living
40 with dementia is projected to reach 152 million by 2050. Cognitive impairment decreases
41 quality of life, increases caregiver burden, and imposes substantial demands on healthcare
42 systems (16). Importantly, the relationship between sleep and cognition is bidirectional. The
43 glymphatic system, which facilitates the clearance of neurotoxic metabolites during sleep,
44 becomes less effective with ageing and sleep disruption (17,18). Both REM and deep NREM
45 sleep stages play essential roles in memory consolidation, learning processes, and emotional
46 regulation (19,20).
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Pharmacological interventions for sleep problems in older adults are associated with important
4 risks, including falls, cognitive impairment, and dependency (21,22). Consequently, safer and
5 more sustainable non-pharmacological approaches have gained increasing attention.
6
7 Aromatherapy, a complementary method involving the therapeutic use of essential oils, has
8 demonstrated potential benefits for sleep regulation and cognitive functioning through its
9 modulatory effects on limbic-system neurotransmitters (23). Although interest in the use of
10 aromatherapy as a non-pharmacological intervention has been increasing, important gaps
11 remain in the literature (23,24). Previous studies have largely examined sleep or cognitive
12 outcomes separately and have predominantly relied on self-reported measures (23-25).
13
14 Furthermore, evidence remains limited regarding inhalation-based aromatherapy protocols that
15 integrate both subjective assessments and objective sleep measurements, particularly in older
16 adults residing in residential care settings, who are at high risk for both sleep disturbances and
17 cognitive decline (24-26).
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 Therefore, there is a need for well-designed randomised controlled trials that simultaneously
34 evaluate sleep patterns and cognitive outcomes using multidimensional assessment approaches.
35
36 The present study aims to address this gap by investigating the effects of a multi-component
37 inhalation aromatherapy protocol on sleep quality, objective sleep parameters, and cognitive
38 performance (specifically attention, memory, and orientation) in older adults living in
39 residential care facilities.
40
41
42
43
44
45
46
47

48 **Objective**

49
50 To evaluate the effects of a multi-component inhalation aromatherapy protocol on sleep quality,
51 sleep architecture (sleep onset latency, total sleep duration, REM duration, N1–N2 duration,
52 N3 duration, night-time awakenings, and daytime sleepiness), and cognitive performance in
53
54
55
56
57
58
59
60 older adults.

Hypothesis

H₁: There is a statistically significant difference between the intervention and control groups, such that older adults receiving inhalation aromatherapy demonstrate improved objective and subjective sleep outcomes and better cognitive performance (orientation, memory, and concentration) compared with the control group.

H₀: There is no statistically significant difference between older adults receiving inhalation aromatherapy and those in the control group in terms of objective and subjective sleep outcomes or cognitive performance (orientation, memory, and concentration).

2. Materials and Methods

2.1. Study Design

This study was a two-arm, parallel-group randomised controlled trial designed to evaluate the effects of inhaled blended aromatherapy on sleep and cognitive outcomes in older adults. The intervention was delivered over four weeks. The trial was reported in accordance with the CONSORT guidelines (Figure 1). Due to the nature of the intervention (inhalation aromatherapy with a distinct scent), full blinding of participants and the implementing researcher was not feasible. Therefore, participants were aware of their group allocation, and the study cannot be considered fully blinded. To minimise potential bias, all participants were followed under standardised conditions, including identical assessment schedules and procedures across groups.

2.2. Participants and Inclusion Criteria

In this randomised controlled trial, 60 older adults residing in a public residential care facility were enrolled. Participants were eligible if they met the following inclusion criteria: (i) aged ≥ 65 years; (ii) no diagnosis of psychiatric illness or severe cognitive impairment; (iii) no

1
2
3 respiratory disease and no known allergy to essential oils; (iv) Epworth Sleepiness Scale (ESS)
4 score ≥ 11 ; and (v) Pittsburgh Sleep Quality Index (PSQI) score > 5 .

5
6
7
8 Exclusion criteria were: (i) use of pharmacological treatments known to affect sleep; (ii) body
9 mass index (BMI) ≥ 30 kg/m²; (iii) severe pain ($\geq 5/10$); and (iv) use of any complementary
10 therapy within the last three months. Participants were withdrawn in the event of adverse effects
11 (e.g., allergic reactions or respiratory distress) or at their own request. Participants with severe
12 cognitive impairment were excluded; however, those with mild cognitive impairment were
13 allowed to participate.

23 2.3. Sample Size and Power Analysis

24
25
26 In this study, sample size estimation was based on the effect size coefficient (Cohen's *d*) as
27 defined by Cohen (27). For the preliminary estimation, findings from the randomised controlled
28 experimental study by Genç et al. (28), which evaluated the effects of aromatherapy on sleep
29 quality and fatigue in older adults, were used. In that study, a significant improvement in
30 Pittsburgh Sleep Quality Index (PSQI) scores was observed following the intervention, with the
31 mean PSQI score in the intervention group decreasing from 8.10 ± 3.13 to 5.06 ± 2.51 ($t =$
32 6.474 , $p < 0.001$). Based on these data, the estimated Cohen's *d* was approximately 1.07,
33 indicating a large effect size.

34
35
36 This effect size was adopted as the reference criterion for the present trial. Power analysis using
37 G*Power 3.1 software (29) was performed with a two-tailed significance level of $\alpha = 0.05$ (95%
38 confidence level), power of 0.99, and effect size $d = 1.07$. Under these assumptions, a minimum
39 of 28 participants per group was required, yielding a total minimum sample size of 56.

40
41
42 To account for potential attrition (e.g., withdrawal, health complications, or noncompliance
43 with the intervention protocol), the target sample size was increased by approximately 7%,
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 resulting in 30 participants per group (total n = 60). Randomisation was stratified by sex to
4
5 ensure balanced allocation of women and men across groups.
6
7

8 **2.4. Research Environment and Ethical Approval**

9
10
11 The study was conducted in a public residential care facility under the supervision of the
12
13 facility's healthcare and care staff. Ethical approval was obtained from the Istanbul Medipol
14
15 University GETAT Clinical Research Ethics Committee (Approval No: E-95961207-
16
17 604.01.01-3755; Date: 15 June 2023). Institutional permission was obtained from the facility
18
19 management, and clinical research permission was obtained from the national competent health
20
21 authority. Written informed consent was obtained from all participants before enrolment.
22
23
24
25

26 **2.5. Randomisation**

27
28
29 Participants were randomly allocated (1:1) to the intervention or control group using sex-
30
31 stratified randomisation. Eligible participants were first stratified by sex (women and men).
32
33 Within each stratum, allocation sequences were generated using a computer-based random
34
35 number generator. Randomisation was conducted by an independent researcher who was not
36
37 involved in outcome assessment. To ensure allocation concealment, the computer-generated
38
39 allocation list was kept by the independent researcher and was not accessible to outcome
40
41 assessors; group assignment was revealed only after enrolment was completed.
42
43
44

45 **2.6. Data Collection Tools**

46
47
48 Multidimensional data-collection instruments were used to obtain comprehensive information
49
50 on subjective and objective sleep outcomes and on cognitive function. Participant demographic
51
52 and clinical characteristics were collected using a researcher-developed Participant Information
53
54 Form. Daytime sleepiness was assessed using the Epworth Sleepiness Scale (ESS), overall sleep
55
56 quality using the Pittsburgh Sleep Quality Index (PSQI), and cognitive performance using the
57
58 Blessed Orientation–Memory–Concentration Test (BOMCT). These instruments were selected
59
60

1
2
3 as validated measures suitable for the clinical and functional characteristics of older adults. All
4
5 questionnaires were administered at baseline (Week 0) and at the end of the intervention (Week
6
7
8 4).

9
10 Following questionnaire administration, objective sleep parameters were recorded using
11
12 wearable smartwatches paired with compatible Android smartphones. Sleep onset time, wake
13
14 time, bedtime, and wake-up time, REM sleep duration, light and deep sleep durations, and total
15
16 sleep time during the night were obtained from the wearable devices.
17
18

19 20 *Participant Information Form*

21
22 A researcher-developed Participant Information Form was prepared based on the relevant
23
24 literature and used to collect sociodemographic and clinical characteristics, including age, sex,
25
26 body mass index (BMI), and chronic diseases. The form consisted of 21 items assessing
27
28 demographic and health-related information (30).
29
30
31

32 33 *Epworth Sleepiness Scale (ESS)*

34
35 The Epworth Sleepiness Scale was developed by Johns (31) to assess daytime sleepiness. It
36
37 includes eight items that evaluate the likelihood of dozing in routine daily situations. Each item
38
39 is scored from 0 (would never doze) to 3 (high chance of dozing), yielding a total score of 0–
40
41 24, with higher scores indicating greater daytime sleepiness. In the present study, Cronbach's
42
43 alpha was 0.737.
44
45
46

47 48 *Pittsburgh Sleep Quality Index (PSQI)*

49
50 The Pittsburgh Sleep Quality Index, developed by Buysse et al. (32), assesses sleep quality and
51
52 sleep disturbances over the preceding month. It comprises seven components and yields a global
53
54 score ranging from 0 to 21; scores ≥ 5 indicate poor sleep quality.
55
56
57

58 59 *Blessed Orientation–Memory–Concentration Test (BOMCT)*

1
2
3 The original Blessed Orientation–Memory–Concentration Test was developed by Blessed,
4 Tomlinson, and Roth (33) and later modified by Katzman et al. (34) into a six-item version
5 assessing cognitive function, including orientation, memory, and attention. Higher scores
6 indicate greater cognitive impairment. Test–retest reliability has been reported as 0.77, and
7 correlation with the Mini-Mental State Examination (MMSE) as 0.83 (35). In the present study,
8 Cronbach’s alpha was 0.758.
9

16 17 *Wearable Smart Devices and Android-Based Application Support*

20
21 Objective sleep parameters were obtained using wearable smart devices (Oppo Watch Free,
22 Oppo, China), which provided continuous measurements of sleep onset latency, total sleep time,
23 and sleep-stage durations (REM, deep sleep [N3], and light sleep [N1–N2]). Data were
24 transferred to Android-based mobile devices via Bluetooth technology.
25

26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Wearable devices incorporating accelerometers and photoplethysmography (PPG) sensors
enable non-invasive monitoring of physical activity, heart rate, and sleep-related parameters
and have been widely recommended for use in both clinical and research settings due to their
practicality, safety, and feasibility (36,37).

Sleep parameters were derived using the device’s proprietary algorithms based on
accelerometer and PPG signals, rather than manually processed raw data. These algorithms
automatically estimate sleep stages and related sleep variables.

Previous studies have demonstrated that consumer wearable devices show acceptable
agreement with polysomnography and can provide reliable estimates of sleep-related
parameters (36,37). In addition, validation studies on OPPO Watch-based sleep analysis
systems have reported good correlation and agreement with clinical reference measurements
(38).

1
2
3 Integrating objective measures with subjective instruments (PSQI and ESS) enabled a
4 multidimensional assessment of sleep outcomes. Data transfer and synchronisation were
5 conducted via Android-based smartphones paired with the wearable devices, and automated
6 acquisition features supported standardisation and data security. Weekly data checks were
7 performed to ensure completeness and accuracy of the recorded measurements.
8
9
10
11
12
13
14

15 **2.7. Intervention**

16 **2.7.1. Essential Oils Used in the Study**

17
18
19 A multi-component inhalation aromatherapy protocol was implemented using vetiver, cedar,
20 clary sage (musk sage), grapefruit, petitgrain (orange), peppermint (English mint), and
21 palmarosa essential oils. All oils were obtained from the same manufacturer and stored in dark,
22 airtight glass bottles under optimal conditions in accordance with expert recommendations and
23 the relevant literature (39).
24
25
26
27
28
29
30
31
32
33

34 Peppermint oil contains bioactive components such as menthol and menthone and has been
35 associated with central nervous system stimulation through cholinesterase inhibition and
36 interactions with GABA-A and nicotinic receptors (40). Clary sage oil, containing linalyl
37 acetate and β -pinene, has demonstrated sedative and antidepressant effects and may reduce
38 cortisol levels when inhaled (41). Vetiver oil, characterised by sesquiterpenes, has been
39 associated with anxiolytic, nootropic, and sleep-modulating effects and may influence sleep–
40 wake regulation and electroencephalographic activity (42).
41
42
43
44
45
46
47
48
49

50 Petitgrain oil contains linalool and myrcene, which may contribute to the regulation of the
51 autonomic nervous system (43). Cedar oil, particularly its cedrol component, has been linked
52 to sleep-onset facilitation via serotonin- and melatonin-related pathways (44). Grapefruit oil
53 contains compounds such as limonene and sabinene and has been associated with
54 neurophysiological effects involving autonomic regulation (45).
55
56
57
58
59
60

Rationale for Multi-Component Blended Oils

The essential oils were selected based on the literature and in consultation with an aromatherapy specialist to develop a protocol targeting both sleep and cognitive outcomes. Previous studies suggest that blending two or more essential oils may enhance therapeutic efficacy compared with single-oil approaches (46,47).

2.7.2. Intervention Protocol

After providing study information, written informed consent was obtained from all participants. Each participant in the intervention group received two labelled essential oil bottles prepared for daytime and nighttime use. Bottles were colour-coded (daytime: grey cap; nighttime: blue cap) and labelled accordingly.

Daytime inhalation was administered at 11:30 using a 1:1 blend of peppermint and palmarosa oils. Night-time inhalation was administered at 21:30 using an equal-proportion blend of vetiver, cedar, clary sage (musk sage), petitgrain, and grapefruit oils. For each session, five drops of the prepared blend were applied to sterile cotton and positioned within the participant's breathing area (approximately 20 cm). Each inhalation session lasted 10 minutes and was supervised by the researcher. Based on prior evidence, the physiological effects of inhalation aromatherapy are known to occur rapidly, typically within minutes after exposure.

All aromatherapy sessions were conducted under strictly standardised conditions. The intervention was administered at fixed times (11:30 and 21:30), in the same residential care setting, using identical materials and procedures. The same researcher supervised all sessions,

1
2
3 and the duration, positioning, and administration method were kept consistent for all
4
5 participants.
6
7
8
9

10 11 **2.7.3. Data Collection and Follow-up**

12
13
14 Objective sleep parameters (total sleep time, sleep onset latency, REM duration, deep sleep
15 [N3] duration, light sleep [N1–N2] duration, and night-time awakenings) were continuously
16
17 monitored using wearable smartwatches. Data were synchronised with Android-based mobile
18
19 devices and checked weekly to ensure completeness and data integrity. Assessments were
20
21 conducted at three time points: baseline (Day 0), mid-intervention (Day 15; device data only),
22
23 and post-intervention (Day 30). Subjective measures (ESS, PSQI, and BOMCT) were
24
25 administered via face-to-face interviews at baseline and post-intervention.
26
27
28
29
30

31 **2.7.4. Intervention Group**

32
33
34 Participants allocated to the intervention group received inhalation aromatherapy twice daily
35
36 (daytime and night-time) for four weeks. All sessions were conducted under the researcher's
37
38 supervision, with standardised timing and monitoring for potential adverse effects. No adverse
39
40 events were observed, and all participants completed the protocol.
41
42
43

44 **2.7.5. Control Group**

45
46
47 Participants in the control group did not receive aromatherapy. However, wearable devices,
48
49 assessment instruments, and the measurement schedule were implemented identically to the
50
51 intervention group to enable isolated evaluation of the aromatherapy effect.
52
53

54
55 Details of the study implementation scheme and intervention schedule are presented in
56
57 Supplementary eTable 1.
58

59 **2.8. Statistical Analysis**

60

1
2
3 All analyses were performed using IBM SPSS Statistics version 28.0 (IBM Corp., Armonk,
4 NY, USA). Descriptive statistics were presented as mean \pm standard deviation, median
5
6 (minimum–maximum), or n (%) as appropriate.
7
8
9

10
11 Between-group comparisons were conducted using Welch's t-test for continuous outcome
12 variables, including total sleep time, sleep onset latency, REM sleep duration, deep sleep (N3),
13 light sleep (N1–N2), number of nocturnal awakenings, daytime sleepiness duration, and
14 questionnaire scores (ESS, PSQI, and BOMCT).
15
16
17
18
19

20
21 Within-group comparisons across repeated measurements (Day 0, Day 15, and Day 30) for
22 objective sleep parameters were analysed using the Friedman test, followed by Bonferroni-
23 adjusted post-hoc comparisons when appropriate.
24
25
26
27
28

29
30 Effect sizes were calculated using Cohen's d for between-group comparisons and Kendall's W
31 for repeated measures analyses. Two-sided p-values <0.05 were considered statistically
32 significant; values <0.001 were reported as $p<0.001$.
33
34
35
36

37 38 **3. Results**

39
40 This study evaluated the effects of inhalation aromatherapy on objective sleep parameters,
41 subjective sleep quality, daytime sleepiness, and cognitive performance among older adults
42 residing in a residential care facility. Results are presented in Table 1–Table 5 and
43 Supplementary eFigure 1.
44
45
46
47
48

49 50 **3.1. Baseline socio-demographic and clinical characteristics**

51
52 Baseline socio-demographic and clinical characteristics of participants in the intervention and
53 control groups are shown in Table 1. The groups were comparable with respect to age, marital
54 status, education level, leisure activities, presence of chronic disease, history of sleep problems,
55
56
57
58
59
60

1
2
3 difficulty falling asleep, frequency of nocturnal awakenings, medication use, and duration of
4 sleep disturbances (all $p > 0.05$; Table 1). However, the distribution of disease types differed
5 significantly between groups ($p = 0.002$), with endocrine disorders more prevalent in the
6 intervention group and cardiovascular and nephrological conditions more common in the
7 control group (Table 1).
8
9

10 11 12 13 14 15 **3.2. Objective sleep parameters and sleep duration**

16
17
18 Objective sleep parameters recorded at baseline (Day 0), mid-intervention (Day 15), and post-
19 intervention (Day 30) are presented in Table 2 and visualised in Supplementary eFigure 1. In
20 the intervention group, significant improvements over time were observed across multiple
21 objective sleep outcomes, including increases in total sleep time, REM duration, and deep sleep
22 (N3) duration, along with reductions in sleep onset latency and the number of nocturnal
23 awakenings (all $p < 0.001$; Table 2). In contrast, no statistically significant changes were
24 observed across time points in the control group (Table 2). Between-group effect sizes indicated
25 large differences for key objective outcomes following the intervention (Table 2).
26
27
28
29
30
31
32
33
34
35
36

37 38 39 **3.3. Subjective sleep quality and daytime sleepiness**

40
41 Subjective daytime sleepiness and sleep quality outcomes are presented in Table 3 and Table
42 4. In the intervention group, ESS scores significantly decreased from baseline to Day 30
43 ($p < 0.001$; Table 3). Similarly, PSQI global scores improved significantly over the intervention
44 period ($p < 0.001$; Table 4). No statistically significant changes were observed in the control
45 group for ESS or PSQI outcomes (Table 3–Table 4). Improvements in the intervention group
46 were observed across PSQI components, including subjective sleep quality, sleep latency, sleep
47 duration, habitual sleep efficiency, sleep disturbances, daytime dysfunction, and use of sleep
48 medication (Table 4).
49
50
51
52
53
54
55
56
57
58
59

60 **3.4. Cognitive outcomes**

Cognitive outcomes assessed using the BOMCT are presented in Table 5. In the intervention group, BOMCT scores improved significantly from baseline to post-intervention ($p < 0.001$; Table 5). The control group showed no improvement over the same period (Table 5).

4. Discussion

This randomised controlled trial evaluated a multi-component inhalation aromatherapy protocol and found improvements in both subjective and objective sleep outcomes, accompanied by better cognitive performance in older adults residing in a residential care facility. Overall, the findings indicate that inhalation-based aromatherapy may represent a feasible non-pharmacological strategy to support sleep and cognition in this population. In this section, the study outcomes are discussed in relation to the current evidence base and plausible neurophysiological mechanisms.

Aromatherapy was associated with increased total sleep time and shorter sleep onset latency. In the intervention group, total sleep duration increased from 322.07 ± 15.28 to 374.57 ± 11.37 minutes, whereas no significant change was observed in the control group. These findings are consistent with prior studies suggesting that essential oils such as lavender, vetiver, and palmarosa can improve sleep initiation and prolong total sleep time, primarily by reducing sleep latency (48,49).

The observed effects may reflect the complementary properties of the blended oils selected in this study. Vetiver has been linked with sedative and anxiolytic effects, palmarosa with calming properties, and peppermint with enhanced alertness and cognitive clarity (24,50). The daytime peppermint–palmarosa application may have contributed to improved daytime functioning and reduced subjective sleepiness, consistent with the decrease in ESS scores in the intervention group (from 11.8 ± 3.01 to 7.53 ± 2.30). This interpretation aligns with evidence that peppermint may influence alertness and attention via olfactory-driven limbic pathways (50).

1
2
3 Notably, aromatherapy also improved sleep architecture. REM duration increased from 42.57
4 ± 8.72 to 71.73 ± 9.91 minutes, and deep sleep (N3) increased from 16.97 ± 6.07 to 42.10 \pm
5 14.50 minutes. Similar effects have been reported in studies suggesting that essential oils such
6 as vetiver and lavender may enhance deep-sleep physiology and delta activity (51). Given the
7 established role of sleep, including REM sleep, in memory consolidation (52,53), the observed
8 increase in REM duration is consistent with concurrent improvements in cognitive
9 performance. Additionally, citrus-based oils such as petitgrain and cedar have been associated
10 with neurophysiological effects that may support sleep regulation (54), supporting the potential
11 benefit of blended oil protocols targeting multiple sleep stages.

12
13
14
15
16
17
18
19
20
21
22
23
24
25 Aromatherapy was also associated with improved sleep continuity, as evidenced by reduced
26 nocturnal awakenings in the intervention group (from 2.23 ± 0.50 to 1.37 ± 0.49). Comparable
27 improvements have been reported in randomised trials using lavender or blended essential oils
28 (49,55,56). One possible mechanism may involve increased parasympathetic activity, which
29 could facilitate physiological readiness for sleep and reduce sleep fragmentation (45).

30
31
32
33
34
35
36
37
38 Consistent with the objective improvements, subjective sleep quality improved substantially.
39 PSQI global scores decreased from 13.97 ± 1.38 to 7.73 ± 1.86 , indicating a meaningful
40 enhancement in perceived sleep quality. These results align with meta-analyses and
41 experimental studies demonstrating the beneficial effects of essential oils on sleep quality in
42 older adults (48,46). Mechanistically, oils containing constituents such as linalool, limonene,
43 and sesquiterpenes may modulate inhibitory neurotransmission, including GABAergic
44 pathways, contributing to sleep-promoting effects (57).

45
46
47
48
49
50
51
52
53
54
55 A particularly important finding of the present study is the concurrent improvement in cognitive
56 performance alongside improvements in REM and N3 sleep. BOMCT scores decreased from
57 12.47 ± 5.10 to 6.80 ± 3.50 in the intervention group, whereas the control group showed no
58
59
60

1
2
3 improvement. This pattern is consistent with evidence that age-related reductions in REM and
4 deep sleep contribute to impairments in memory, attention, and orientation (52,53). The present
5 findings suggest that supporting sleep architecture through aromatherapy may also have
6 downstream benefits for cognitive functioning in older adults.
7
8
9

10
11
12
13 In addition, aromatherapy may influence cognitive outcomes both directly, through olfactory-
14 mediated neural processing, and indirectly, through improvements in sleep quality and
15 continuity (58,59).
16
17
18
19
20

21
22 Beyond statistical significance, the magnitude of improvement observed in BOMCT scores
23 suggests potential clinical relevance, particularly in domains such as orientation, memory, and
24 attention. However, given that BOMCT is a screening instrument, further studies using
25 comprehensive neuropsychological assessments are needed to confirm the clinical significance
26 of these findings.
27
28
29
30
31
32

33
34 Neurobiological mechanisms underlying these effects have been discussed in prior research.
35 Essential oils such as vetiver, lavender, and cedar have been reported to influence GABAergic
36 and serotonergic pathways and may contribute to anxiolytic and neuroprotective effects (57).
37 In addition, aromatherapy may influence cognitive outcomes both directly, through olfactory-
38 mediated neural processing, and indirectly, through improvements in sleep quality and
39 continuity (58,59).
40
41
42
43
44
45
46
47
48

49
50 The findings of the present study are largely consistent with previous research demonstrating
51 the beneficial effects of aromatherapy on sleep quality and duration in older adults (48,55).
52 However, the present study differs from much of the existing literature in several important
53 aspects. While many previous studies have relied primarily on subjective assessments, this
54 study integrated subjective measures with objective sleep data from wearable devices (59). In
55
56
57
58
59
60

1
2
3 addition, the use of a multi-component, circadian-aligned aromatherapy protocol and the
4
5 concurrent evaluation of cognitive outcomes represent key methodological strengths and novel
6
7 contributions.
8
9

10
11 Taken together, the findings indicate that a multi-component inhalation aromatherapy protocol
12
13 may improve sleep quality, sleep architecture, and cognitive outcomes in older adults.
14
15 Aromatherapy may be considered a relatively safe and practical complementary nursing
16
17 intervention in residential care settings; however, replication in larger, more diverse samples is
18
19 warranted to confirm generalisability and clarify mechanisms and long-term effects. Despite
20
21 these findings, the literature highlights methodological challenges in aromatherapy research,
22
23 particularly regarding blinding and placebo control, given the perceptible nature of scent (56). In
24
25 studies of aromatherapy administered via inhalation, it is methodologically challenging to
26
27 ensure appropriate blinding due to the perceptible nature of the scent.
28
29
30
31

32
33 Although no adverse events were observed in this study, the safety and feasibility of
34
35 aromatherapy in populations with sensitive conditions or chronic illnesses should be interpreted
36
37 with caution. No unexpected or unanticipated effects were observed during the intervention
38
39 period. Participants were systematically monitored for potential adverse responses, including
40
41 respiratory discomfort, headache, dizziness, or irritation; however, none were reported.
42
43
44

45
46 Due to the study design, individuals with severe respiratory disease and those with known
47
48 allergies to essential oils were excluded; therefore, the generalisability of the findings to more
49
50 clinically vulnerable populations with multiple comorbidities is limited.
51
52

53
54 Essential oils contain biologically active compounds and may affect neurophysiological
55
56 processes and the autonomic nervous system (57). However, adverse effects associated with
57
58 their use, including allergic reactions, skin irritation, phototoxicity, and, in rare cases, systemic
59
60

1
2
3 toxicity, have been reported in the literature. In addition, certain essential oils may pose
4 potential risks and lead to drug interactions in specific patient groups, such as pregnant women,
5
6 individuals with epilepsy, or those receiving multiple medications (57).
7
8
9

10
11 The present findings suggest that inhalation aromatherapy may be considered a practical
12 complementary approach to support sleep quality and cognitive functioning in older adults,
13 particularly in settings where pharmacological treatments are limited by adverse effects such as
14 falls, residual daytime sedation, and drug interactions (60). Given its non-invasive nature,
15 relatively low cost, and ease of implementation, aromatherapy may be integrated into routine
16 nursing care in residential and home care settings. The use of circadian-aligned daytime and
17 nighttime blends may provide an additional advantage in symptom management. Although
18 psychosocial outcomes were not directly assessed, improvements in sleep quality and daytime
19 alertness may indirectly support daily functioning and social engagement. At a broader level,
20 scalable supportive interventions that enhance sleep and cognitive functioning in later life may
21 contribute to healthy ageing and reduce the burden on healthcare and social care systems.
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

37 **5. Clinical implications**

38
39
40
41 The present findings suggest that inhalation aromatherapy may be considered as a practical
42 complementary approach to support sleep quality and cognitive functioning in older adults,
43 particularly in settings where pharmacological sleep treatments may be limited by adverse
44 effects such as falls, residual daytime sedation, and polypharmacy-related interactions. Given
45 its non-invasive administration, low cost, and feasibility, aromatherapy could be integrated into
46 routine nursing care in residential care facilities and home-care services.
47
48
49
50
51
52
53
54

55
56 The use of distinct daytime and nighttime blends may also represent a circadian-aligned
57 approach to symptom management. Although psychosocial outcomes were not formally
58 measured, improvements in sleep and daytime alertness may contribute to better daytime
59
60

1
2
3 functioning and social engagement. At a broader level, scalable supportive interventions that
4 enhance sleep and cognitive functioning in later life may contribute to healthy ageing and may
5
6 reduce the burden on health and social care systems.
7
8
9

10 **6. Limitations**

11
12
13
14 Several limitations should be considered when interpreting the findings of this study. First, the
15 sample was drawn from a single residential care facility, which may limit the generalisability
16
17 of the results to community-dwelling older adults or populations with different sociocultural
18
19 and clinical characteristics. In addition, participation was voluntary, which may introduce
20
21 selection bias.
22
23
24

25
26
27 Second, the study population consisted of older adults, a group often characterised by
28
29 multimorbidity, physiological vulnerability, and polypharmacy. Although individuals with
30
31 severe respiratory disease and known allergies to essential oils were excluded, the presence of
32
33 chronic conditions may influence both responsiveness to the intervention and susceptibility to
34
35 potential adverse effects. Therefore, the safety and applicability of the findings in more
36
37 clinically complex older populations should be interpreted with caution.
38
39
40

41
42 Third, objective sleep outcomes were obtained using wearable devices based on accelerometer
43
44 and photoplethysmography algorithms. Although these devices are practical and suitable for
45
46 continuous monitoring, they may have limited accuracy compared with gold-standard
47
48 polysomnography, particularly for detailed sleep-stage classification.
49
50

51
52 Fourth, the intervention involved a multi-component essential oil protocol; therefore, the
53
54 independent effects of individual oils could not be determined. In addition, individual
55
56 differences such as odour sensitivity and prior exposure to essential oils were not assessed and
57
58 may have influenced the results.
59
60

1
2
3 Fifth, due to the perceptible nature of aromatherapy, blinding of participants and the
4 implementing researcher was not feasible. This may have introduced placebo effects or
5 expectation bias. Although objective sleep measures were used to reduce reliance on subjective
6 reporting, the potential influence of such bias cannot be completely excluded. In addition, no
7 active placebo or attention-control procedure was applied to the control group, which may
8 further contribute to expectation bias. Furthermore, although efforts were made to minimise
9 cross-contamination by accommodating participants in separate residential blocks, interactions
10 within the same institutional setting could not be fully controlled.
11
12

13
14 Finally, cognitive outcomes were assessed using a single screening instrument (BOMCT), and
15 a post-intervention follow-up period was not included. Therefore, the long-term sustainability
16 of the observed effects and the clinical significance of cognitive improvements should be
17 interpreted with caution. Future studies should incorporate longer follow-up periods and more
18 comprehensive neuropsychological assessments in diverse and clinically complex populations.
19
20
21

22 23 24 25 26 27 28 29 30 31 32 33 34 35 **7. Contribution to the Literature** 36

37
38 This study adds to the growing evidence on inhalation aromatherapy by evaluating both sleep-
39 related outcomes and cognitive performance within a single randomised controlled design in
40 older adults. Unlike many previous studies focusing on either subjective sleep quality or
41 cognition alone, the present trial integrated validated subjective measures (PSQI, ESS,
42 BOMCT) with objective wearable-derived sleep parameters, enabling a more comprehensive
43 assessment of intervention effects.
44
45
46
47
48
49
50
51

52
53 An additional contribution is the use of distinct day- and night-specific essential oil blends,
54 designed to align with circadian patterns. The concurrent improvements in REM and deep sleep
55 (N3) durations, alongside enhanced cognitive performance, suggest that aromatherapy may
56 influence neurocognitive functioning through sleep-related pathways. Overall, these findings
57
58
59
60

1
2
3 support considering aromatherapy not only as a relaxation approach but also as a potentially
4 structured complementary intervention targeting sleep architecture and cognitive outcomes.
5
6
7 Future studies should replicate these findings in broader populations and explore underlying
8 mechanisms using longer follow-up designs and advanced assessment approaches.
9
10
11
12

13 **9. Conclusion**

14
15
16 In this randomised controlled trial, a multi-component inhalation aromatherapy protocol was
17 associated with significant improvements in sleep outcomes and cognitive performance among
18 older adults residing in a residential care facility. Compared with controls, the intervention
19 improved subjective sleep quality (PSQI) and daytime sleepiness (ESS), and enhanced
20 objective sleep architecture, including increased total sleep time, REM duration, and deep sleep
21 (N3) duration, alongside reduced sleep onset latency and nocturnal awakenings. Cognitive
22 performance also improved significantly, as indicated by BOMCT scores. No adverse events
23 were observed during the intervention period. These findings suggest that inhalation
24 aromatherapy may be a feasible complementary approach to support sleep and cognition in
25 older adults; further studies with larger samples and longer follow-up are warranted.
26
27
28
29
30
31
32
33
34
35
36
37
38
39

40 **10. Clinical Contributions and Implementation Recommendations**

41
42 Given the risks of pharmacological sleep treatments in later life, inhalation aromatherapy may
43 be a practical complementary nursing intervention, given its low cost, non-invasive delivery,
44 and ease of implementation. A protocol using daytime and night-time blends may support
45 circadian-aligned symptom management. Implementation in routine care would require basic
46 staff training, attention to individual factors (e.g., allergy history and odour sensitivity), and
47 standardised monitoring to ensure safety and adherence.
48
49
50
51
52
53
54
55
56

57 **DECLARATIONS**

58 **Ethics approval and consent to participate**

59
60

1
2
3 This study was approved by an institutional clinical research ethics committee (Approval No:
4 E-95961207-604.01.01-3755; Date: 15 June 2023) and authorised by the national competent
5 health authority. Institutional permission was obtained from the management of the residential
6 care facility where the study was conducted. The overall study was carried out between January
7 2024 and March 2025, and written informed consent was obtained from all participants before
8 enrolment. Participant confidentiality was maintained throughout the study.
9

17 **Consent for publication**

20 Not applicable.

23 **Data Availability Statement**

26 All data used in this study are available from the corresponding author upon reasonable
27 scientific request. Shared data will be anonymised and stripped of all personal identifiers in
28 accordance with confidentiality principles and institutional regulations.
29

34 **Competing interests**

37 The authors declare that they have no competing interests.

40 **Funding**

43 This study was supported by an institutional research grant (Project No: 2024/20). The funding
44 covered the implementation of the study, the acquisition of materials, and the costs of statistical
45 analysis.
46

50 **Authors' contributions**

- 53 • **Belçim Ede Sarıkaya:** Data curation, Investigation, Visualization, Writing – original
54 draft, Writing – review & editing
55
56
57
58
59
60

- 1
- 2
- 3 • **Sebahat Ateş:** Conceptualization, Formal analysis, Methodology, Validation,
- 4 Supervision, Writing – review & editing
- 5
- 6
- 7
- 8 • **Tuğba Kaman:** Methodology, Resources, Investigation
- 9
- 10
- 11 • **Ayşe Arzu Sayın Şakul:** Resources, Methodology
- 12
- 13

14 **Trial registration**

15
16
17 This randomised controlled trial was registered in the ClinicalTrials.gov database (**Identifier:**
18 **NCT06208800**). The registration process was completed in accordance with international
19 ethical standards.
20
21
22
23

24 **Acknowledgements**

25
26
27 The authors would like to thank the healthcare personnel, the older adults who volunteered, the
28 representatives of the institutions that supported the research, and the statistical consultants who
29 provided technical support during data analysis.
30
31
32
33

34 **REFERENCES**

- 35
36
37
38
39 1. Turkish Statistical Institute (TURKSTAT). Turkish Statistical Institute; 2021. Available
40 from: <https://www.tuik.gov.tr>.
- 41
42
43 2. World Health Organization (WHO). Dementia: key facts; 2020. Available from:
44 <https://www.who.int/news-room/fact-sheets/detail/dementia>.
- 45
46
47 3. Dzierzewski JM, Dautovich N, Ravyts S. Sleep and cognition in older adults. *Sleep Med*
48 *Clin.* 2018;13(1):93–106. <https://doi.org/10.1016/j.jsmc.2017.09.009>.
- 49
50
51 4. Yaremchuk K. Sleep disorders in the elderly. *Clin Geriatr Med.* 2018;34(2):205–216.
52 <https://doi.org/10.1016/j.cger.2018.01.008>.
- 53
54
55
56
57
58
59
60

- 1
2
3 **5.** Shi L, Chen SJ, Ma MY, et al. Sleep disturbances increase the risk of dementia: a systematic
4 review and meta-analysis. *Sleep Med Rev.* 2018;40:4–16.
5
6 <https://doi.org/10.1016/j.smrv.2017.06.010>.
7
8
- 9
10 **6.** Patel D, Steinberg J, Patel P. Insomnia in the elderly: a review. *J Clin Sleep Med.*
11 2018;14(6):1017–1024. <https://doi.org/10.5664/jcsm.7172>.
12
13
- 14 **7.** Fu T, Guo R, Wang H, et al. The prevalence and risk factors of sleep disturbances in
15 community-dwelling older adults: a systematic review and meta-analysis. *Sleep Breath.*
16 2025;29:110. <https://doi.org/10.1007/s11325-025-03267-6>.
17
18
- 19 **8.** Kizilarlanoglu MC, Cankurtaran M. Rational approach to the management of sleep disorders
20 in the elderly. *Turkiye Klinikleri J Geriatr Spec Top.* 2015;1(1):56–64.
21
22
- 23 **9.** Cardinali DP, Brown GM, Pandi-Perumal SR. Melatonin's benefits and risks as a therapy for
24 sleep disturbances in the elderly: current insights. *Nat Sci Sleep.* 2022;14:1843–1855.
25
26 <https://doi.org/10.2147/NSS.S380465>.
27
28
- 29 **10.** Tatineny P, Shafi F, Gohar A, Bhat A. Sleep in the elderly. *Mo Med.* 2020;117(5):490–495.
30
31
- 32 **11.** Fortier-Brochu É, Morin CM. Cognitive impairment in individuals with insomnia: clinical
33 significance and correlates. *Sleep.* 2014;37(11):1787–1798. <https://doi.org/10.5665/sleep.4172>.
34
35
- 36 **12.** Bubu OM, Brannick M, Mortimer J, et al. Sleep, cognitive impairment, and Alzheimer's
37 disease: a systematic review and meta-analysis. *Sleep.* 2017;40(1):zsw032.
38
39 <https://doi.org/10.1093/sleep/zsw032>.
40
41
- 42 **13.** Havekes R, Abel T. The tired hippocampus: the molecular impact of sleep deprivation on
43 hippocampal function. *Curr Opin Neurobiol.* 2017;44:13–19.
44
45 <https://doi.org/10.1016/j.conb.2017.02.005>.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 **14.** Blazer DG, Yaffe K, Karlawish J. Cognitive aging: a report from the Institute of Medicine.
4
5 JAMA. 2015;313(21):2121–2122. <https://doi.org/10.1001/jama.2015.4380>.
6
7
- 8 **15.** Fjell AM, Walhovd KB. Structural brain changes in aging: courses, causes and cognitive
9
10 consequences. *Rev Neurosci.* 2010;21(3):187–221.
11
12 <https://doi.org/10.1515/REVNEURO.2010.21.3.187>.
13
14
- 15 **16.** GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of
16
17 dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of
18
19 Disease Study 2019. *Lancet Public Health.* 2022;7(2):e105–e125.
20
21 [https://doi.org/10.1016/S2468-2667\(21\)00249-8](https://doi.org/10.1016/S2468-2667(21)00249-8).
22
23
- 24 **17.** Wang J, Zhou Y, Zhang K, et al. Glymphatic function plays a protective role in ageing-
25
26 related cognitive decline. *Age Ageing.* 2023;52(7):afad107.
27
28 <https://doi.org/10.1093/ageing/afad107>.
29
30
- 31 **18.** Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. *Science.*
32
33 2013;342(6156):373–377. <https://doi.org/10.1126/science.1241224>.
34
35
36
- 37 **19.** Mander BA, Winer JR, Walker MP. Sleep and human aging. *Neuron.* 2017;94(1):19–36.
38
39 <https://doi.org/10.1016/j.neuron.2017.02.004>.
40
41
42
- 43 **20.** Balsamo F, Di Giacomo D, Sergi G, Ventriglia F, Martini A. The complex relationship
44
45 between sleep and cognitive reserve in aging: a systematic review. *Brain Sci.* 2024;14(7):654.
46
47 <https://doi.org/10.3390/brainsci14070654>.
48
49
- 50 **21.** Tannenbaum C, Diaby V, Singh D, et al. Sedative-hypnotic medicines and falls in
51
52 community-dwelling older adults: a cost-effectiveness analysis from a US Medicare
53
54 perspective. *Drugs Aging.* 2015;32(4):305–314. <https://doi.org/10.1007/s40266-015-0251-3>.
55
56
57
58
59
60

- 1
2
3 **22.** Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication
4 classes on falls in elderly persons. *Arch Intern Med.* 2009;169(21):1952–1960.
5
6 <https://doi.org/10.1001/archinternmed.2009.357>.
7
8
9
10 **23.** Cheong MJ, Kim S, Kim JS, et al. A systematic literature review and meta-analysis of the
11 clinical effects of aroma inhalation therapy on sleep problems. *Medicine (Baltimore).*
12 2021;100(9):e24652. <https://doi.org/10.1097/MD.00000000000024652>.
13
14
15
16
17 **24.** Sattayakhom A, Wichit S, Koomhin P. The effects of essential oils on the nervous system:
18 a scoping review. *Molecules.* 2023;28(9):3771. <https://doi.org/10.3390/molecules28093771>.
19
20
21
22
23 **25.** Lizarraga-Valderrama LR. Effects of essential oils on central nervous system: focus on
24 mental health. *Phytother Res.* 2021;35(2):657–679. <https://doi.org/10.1002/ptr.6854>.
25
26
27
28
29 **26.** Lee KB, Latif S, Kang YS. Differences in neurotransmitters level as biomarker on sleep
30 effects in dementia patients with insomnia after essential oils treatment. *Biomol Ther (Seoul).*
31 2023;31(3):298–305. <https://doi.org/10.4062/biomolther.2023.014>.
32
33
34
35
36 **27.** Cohen J. *Statistical power analysis for the behavioral sciences.* 2nd ed. Hillsdale, NJ:
37 Lawrence Erlbaum Associates; 1988.
38
39
40
41 **28.** Genç F, Karadağ S, Kılıç Akça N, Tan M, Cerit D. The effect of aromatherapy on the sleep
42 quality and fatigue levels of the elderly: a randomized controlled study. *Holist Nurs Pract.*
43 2020;34(3):155–162. <https://doi.org/10.1097/HNP.0000000000000387>.
44
45
46
47
48
49 **29.** Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1:
50 tests for correlation and regression analyses. *Behav Res Methods.* 2009;41(4):1149–1160.
51
52 <https://doi.org/10.3758/BRM.41.4.1149>.
53
54
55
56
57 **30.** Aydın Yıldırım T, Kitiş Y. Huzurevinde kalan yaşlılarda aromaterapi uygulamasının bilişsel
58 işlevler ve gündüz uykululuğuna etkisi. *Bütüncül Hemşirelik Uygulaması.* 2020;34(2):83–90.
59
60

- 1
2
3 **31.** Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale.
4
5 Sleep. 1991;14(6):540–545.
6
7
- 8 **32.** Buysse DJ, Reynolds CF, Monk TH, et al. The Pittsburgh Sleep Quality Index: a new
9
10 instrument for psychiatric practice and research. *Psychiatry Res.* 1989;28:193–213.
11
12 [https://doi.org/10.1016/0165-1781\(89\)90047-4](https://doi.org/10.1016/0165-1781(89)90047-4).
13
14
- 15 **33.** Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of
16
17 dementia and of senile change in the cerebral grey matter of elderly subjects. *Br J Psychiatry.*
18
19 1968;114(512):797–811. <https://doi.org/10.1192/bjp.114.512.797>.
20
21
22
- 23 **34.** Katzman R, Brown T, Fuld P, et al. Validation of a short Orientation-Memory-
24
25 Concentration Test of cognitive impairment. *Am J Psychiatry.* 1983;140(6):734–739.
26
27
- 28 **35.** Fillenbaum GG, Heyman A, Wilkinson WE, Haynes CS. Comparison of two screening tests
29
30 in Alzheimer’s disease: the correlation and reliability of the Mini-Mental State Examination
31
32 and the modified Blessed test. *Arch Neurol.* 1987;44(9):924–927.
33
34 <https://doi.org/10.1001/archneur.1987.0052021002601>.
35
36
37
- 38 **36.** de Zambotti M, Cellini N, Goldstone A, Colrain IM, Baker FC. Wearable sleep technology
39
40 in clinical and research settings. *Med Sci Sports Exerc.* 2019;51(7):1538–1557.
41
42 <https://doi.org/10.1249/MSS.0000000000001947>
43
44
- 45 **37.** Chinoy ED, Cuellar JA, Huwa KE, et al. Performance of seven consumer sleep-tracking
46
47 devices compared with polysomnography. *Sleep.* 2021;44(5):zsaa291.
48
49 <https://doi.org/10.1093/sleep/zsaa291>
50
51
52
- 53 **38.** Zhou G, Zhao W, Zhang Y, Zhou W, Yan H, Wei Y, et al. Comparison of OPPO Watch
54
55 Sleep Analyzer and polysomnography for obstructive sleep apnea screening. *Nature and*
56
57 *Science of Sleep.* 2024;16:125–141. <https://doi.org/10.2147/NSS.S438065>
58
59
60

- 1
2
3 **39.** Lillehei AS, Halcon LL. A systematic review of the effect of inhaled essential oils on sleep.
4
5 J Altern Complement Med. 2014;20(6):441–451. <https://doi.org/10.1089/acm.2013.0311>.
6
7
8 **40.** Soleimani M, Kashfi LS, Mirmohamadkhani M, Ghods AA. The effect of aromatherapy
9
10 with peppermint essential oil on anxiety of cardiac patients in emergency department: a
11
12 placebo-controlled study. Complement Ther Clin Pract. 2022;46:101533.
13
14 <https://doi.org/10.1016/j.ctcp.2021.101533>.
15
16
17
18 **41.** Seol GH, Shim HS, Kim PJ, et al. Antidepressant-like effect of *Salvia sclarea* is explained
19
20 by modulation of dopamine activities in rats. J Ethnopharmacol. 2010;130(1):187–190.
21
22 <https://doi.org/10.1016/j.jep.2010.04.038>.
23
24
25
26 **42.** Cheaha D, Issuriya A, Manor R, et al. Modification of sleep–waking and
27
28 electroencephalogram induced by vetiver essential oil inhalation. J Intercult Ethnopharmacol.
29
30 2016;5(1):72–78. <https://doi.org/10.5455/jice.20160208050736>.
31
32
33
34 **43.** Huang L, Capdevila L. Aromatherapy improves work performance through balancing the
35
36 autonomic nervous system. J Altern Complement Med. 2017;23(3):214–221.
37
38 <https://doi.org/10.1089/acm.2016.0061>.
39
40
41
42 **44.** Dayawansa S, King R, Zhang X. Autonomic responses during inhalation of natural
43
44 fragrance of cedrol in humans. J Altern Complement Med. 2003;9(3):379–385.
45
46
47
48 **45.** Nagai K, Nijima A, Horii Y, Shen J, Tanida M. Olfactory stimulation with grapefruit and
49
50 lavender oils changes autonomic nerve activity and physiological function. Auton Neurosci.
51
52 2014;185:29–35. <https://doi.org/10.1016/j.autneu.2014.06.005>.
53
54
55
56 **46.** Chang MY, Chen CH, Huang KF. The effects of aromatherapy on sleep improvement: a
57
58 systematic review and meta-analysis. Complement Ther Med. 2025;78:102992.
59
60 <https://doi.org/10.1016/j.ctim.2024.102992>.

- 1
2
3 **47.** Bassolé IH, Juliani HR. Essential oils in combination and their antimicrobial properties.
4
5 *Molecules*. 2012;17(4):3989-4006. doi:10.3390/molecules17043989.
6
7
8
9 **48.** Xu K, Wang S, Ji Q, et al. Effects of aromatherapy on sleep quality in older adults: a meta-
10
11 analysis. *Medicine*. 2024;103(49):e40688. <https://doi.org/10.1097/MD.000000000040688>.
12
13
14 **49.** Nasiri A, Fahimzade L. The effect of inhalation aromatherapy with lavender on sleep quality
15
16 of the elderly in nursing care homes: a randomized clinical trial. *Mod Care J*.
17
18 2017;14(4):e61602. <https://doi.org/10.5812/modernc.61602>.
19
20
21 **50.** Moss M, Hewitt S, Moss L, Wesnes K. Modulation of cognitive performance and mood by
22
23 aromas of peppermint and ylang-ylang. *Int J Neurosci*. 2008;118(1):59–77.
24
25 <https://doi.org/10.1080/00207450601042094>.
26
27
28
29 **51.** Ko LW, Su CH, Yang MH, Liu SY, Su TP. A pilot study on essential oil aroma stimulation
30
31 for enhancing slow-wave EEG in sleeping brain. *Sci Rep*. 2021;11:1078.
32
33 <https://doi.org/10.1038/s41598-020-80171-x>.
34
35
36
37 **52.** Diekelmann S, Born J. The memory function of sleep. *Nat Rev Neurosci*. 2010;11(2):114–
38
39 26. <https://doi.org/10.1038/nrn2762>.
40
41
42 **53.** Scullin MK, Bliwise DL. Sleep, cognition and normal aging: integrating a half century of
43
44 multidisciplinary research. *Perspect Psychol Sci*. 2015;10:97–137.
45
46
47 **54.** Agarwal P, Sebghatollahi Z, Kamal M, et al. Citrus essential oils in aromatherapy:
48
49 therapeutic effects and mechanisms. *Antioxidants*. 2022;11(12):2374.
50
51 <https://doi.org/10.3390/antiox11122374>.
52
53
54
55 **55.** Faydalı S, Çetinkaya F. The effect of aromatherapy on the sleep quality of elderly residents
56
57 of nursing homes. *Holist Nurs Pract*. 2018;32(1):8-16. doi:10.1097/HNP.000000000000248.
58
59
60

- 1
2
3 **56.** Lee, J., & Hur, M. H. (2022). The Effects of Aroma Essential Oil Inhalation on Stress, Pain,
4 and Sleep Quality in Laparoscopic Cholecystectomy Patients: A Randomized Controlled Trial.
5 Asian nursing research, 16(1), 1–8. <https://doi.org/10.1016/j.anr.2021.11.002>
6
7
8
9
10
11 **57.** Hartley N, McLachlan CS. Aromas influencing the GABAergic system. *Molecules*.
12 2022;27(8):2414. doi:10.3390/molecules27082414.
13
14
15
16 **58.** Su G, Liu F, Yang X, et al. The effect of inhaled aromatherapy on cognitive function in
17 patients with cognitive impairment. *Gen Hosp Psychiatry*. 2025;83:34–42.
18 <https://doi.org/10.1016/j.genhosppsy.2025.01.002>.
19
20
21
22
23 **59.** Woo CC, Miranda B, Sathishkumar M, Dehkordi-Vakil F, Yassa MA, Leon M. Overnight
24 olfactory enrichment using an odorant diffuser improves memory and modifies the uncinate
25 fasciculus in older adults. *Front Neurosci*. 2023;17:1200448.
26 <https://doi.org/10.3389/fnins.2023.1200448>.
27
28
29
30
31
32
33 **60.** Glass J, Lanctôt KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older
34 people with insomnia: meta-analysis of risks and benefits. *BMJ*. 2005;331(7526):1169.
35 <https://doi.org/10.1136/bmj.38623.768588.47>
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **TABLES**
4
5

6 **Table 1.** Findings Related to Socio-Demographic and Clinical Characteristics of the
7
8 Participants in the Intervention and Control Groups
9

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Variable	Intervention (n=30), n (%)	Control (n=30), n (%)	χ^2 ; p
Age group			
65–74 years	17 (56.7)	15 (50.0)	Fisher's exact test = 0.796 p = 0.796
75–84 years	13 (43.3)	15 (50.0)	
Marital status			
Married / Widowed	28 (93.3)	30 (100.0)	Fisher's exact test = 0.492, p = 0.472
Single / Divorced / Never married	2 (6.7)	0 (0.0)	
Education level			
Illiterate	9 (30.0)	7 (23.3)	$\chi^2=3.793$; p=0.285
Primary school	16 (53.3)	19 (63.3)	
High school	5 (16.7)	2 (6.7)	
University	0 (0.0)	2 (6.7)	
Leisure time activities			

Physical activity + hobby + social activity + worship	10 (33.3)	7 (23.3)	Fisher's exact test = 0.567 p=0.567
Hobby (watching TV) + social activity	20 (66.7)	23 (76.7)	
Chronic disease			
Yes	26 (86.7)	28 (93.3)	Fisher's exact test=0.671 p=0.667
No	4 (13.3)	2 (6.7)	
Sleep problems			
Yes	24 (80.0)	25 (83.3)	Fisher's exact test = 1.000; p=1.000
No	6 (20.0)	5 (16.7)	
Sleep problem duration			
1–6 months	23 (76.7)	20 (66.7)	Fisher's exact test = 0.567; p=0.567
≥6 months	7 (23.3)	10 (33.3)	
Previous use of sleep medication			
Yes	3 (10.0)	6 (20.0)	
No	27 (90.0)	24 (80.0)	

Downloaded from https://academic.oup.com/biomedgerontology/advance-article/doi/10.1093/gerona/glag105/8659585 by guest on 08 May 2026

			Fisher's exact test=0.472; p=0.470
Difficulty falling asleep			
Yes	21 (70.0)	19 (63.3)	Fisher's exact test=0.785; p=0.784
No	9 (30.0)	11 (36.7)	
Ability to sleep comfortably at night			
Yes	7 (23.3)	9 (30.0)	Fisher's exact test=0.771; p=0.770
No	23 (76.7)	21 (70.0)	
Frequent awakening at night			
Yes	19 (63.3)	22 (73.3)	Fisher's exact test=0.580; p=0.579
No	11 (36.7)	8 (26.7)	
Reason for waking up at night			
Pain	0 (0.0)	2 (6.7)	$\chi^2=2.85$; p=0.416
Stress	6 (20.0)	7 (23.3)	
Toilet requirement	11 (36.7)	12 (40.0)	
Environmental factors	13 (43.3)	9 (30.0)	

Regular medication use			
Yes	28 (93.3)	28 (93.3)	Fisher's exact test=1.000; p=1.000
No	2 (6.7)	2 (6.7)	
Pain \geq5/10			
Yes	0 (0.0)	0 (0.0)	Fisher's exact test=1.000; p=1.000
No	30 (100.0)	30 (100.0)	

Values are n (%).

*Fisher's exact test. †Chi-square test.

Table 2. Mean Values and Temporal Changes in Sleep Characteristics of the Intervention and Control Groups with Statistical Comparisons (Day 0, Day 15, and Day 30)

Outcome	Day	Intervention (n=30) Mean ± SD	Control (n=30) Mean ± SD	Welch's t	p value†	Cohen's d‡
Time to fall asleep (min)	0	63.93 ± 8.82	61.53 ± 10.66	0.950	0.346	0.245
	15	46.57 ± 6.09	62.47 ± 11.01	-6.922	<0.001	-1.787
	30	38.87 ± 6.13	63.83 ± 9.82	-11.811	<0.001	-3.050
Test value		54.200	1.061			
p value		0.000	0.588			
Post-hoc		a>b>c	–			
Post-hoc power		0.998	0.092			
Eta squared		0.183	–			
Total sleep time (min)	0	322.07 ± 15.28	334.57 ± 20.12	-2.710	0.009	-0.700

	15	356.93 ± 14.40	343.50 ± 21.59	2.835	0.007	0.732
	30	374.57 ± 11.37	338.03 ± 16.04	10.177	<0.001	2.628
Test value		47.267	1.865			
p value		0.000	0.394			
Post-hoc		a<b<c	–			
Post-hoc power		0.995	0.127			
Eta squared		0.179	–			
REM sleep duration (min)	0	42.57 ± 8.72	41.50 ± 7.42	0.510	0.612	0.132
	15	59.03 ± 9.61	40.43 ± 7.28	8.451	<0.001	2.182
	30	71.73 ± 9.91	44.07 ± 9.63	10.964	<0.001	2.831
Test value		58.067	1.155			
p value		0.000	0.561			
Post-hoc		a<b<c	–			
Post-hoc power		0.999	0.096			

Eta squared		0.273	-			
Light sleep (N1–N2) duration (min)	0	262.53 ± 15.35	263.13 ± 14.93	-0.153	0.879	-0.040
	15	268.27 ± 12.51	272.93 ± 17.65	-1.182	0.243	-0.305
	30	260.73 ± 12.52	263.77 ± 13.02	-0.920	0.362	-0.237
Test value		28.466	3.509			
p value		0.000	0.173			
Post-hoc		a=c<b	-			
Post-hoc power		0.932	0.202			
Eta squared		0.212	-			
Deep sleep (N3) duration (min)	0	16.97 ± 6.07	29.93 ± 14.80	-4.440	<0.001	-1.146
	15	29.63 ± 6.57	30.13 ± 9.59	-0.236	0.815	-0.061
	30	42.10 ± 14.50	30.20 ± 9.16	3.800	<0.001	0.981
Test value		44.866	0.622			
p value		0.000	0.733			

Post-hoc		a<b<c	–			
Post-hoc power		0.992	0.074			
Eta squared		0.218	–			
Number of night-time awakenings	0	2.23 ± 0.50	2.37 ± 0.61	-0.918	0.362	-0.237
	15	1.70 ± 0.47	2.33 ± 0.55	-4.829	<0.001	-1.247
	30	1.37 ± 0.49	2.43 ± 0.50	-8.310	<0.001	-2.146
Test value		30.100	1.750			
p value		0.000	0.417			
Post-hoc		a>b>c	–			
Post-hoc power		0.944	0.122			
Eta squared		0.150	–			
Daytime sleepiness duration (min)	0	64.30 ± 4.28	64.27 ± 7.66	0.021	0.983	0.005
	15	51.60 ± 7.95	67.90 ± 10.51	-6.775	<0.001	-1.749
	30	47.43 ± 9.07	71.13 ± 14.66	-7.529	<0.001	-1.944

Downloaded from https://academic.oup.com/biomedgerontology/advance-article/doi/10.1093/gerona/glag105/8659585 by guest on 08 May 2026

Test value	50.235	3.681
p value	0.000	0.159
Post-hoc	a>b>c	–
Post-hoc power	0.997	0.210
Eta squared	0.133	–

Values are mean \pm SD.

†Between-group comparisons were performed using Welch's t-test. p values <0.001 are reported as <0.001.

‡Cohen's d represents the between-group effect size (intervention vs control) at each time point; negative values indicate a reduction in the intervention group relative to control

Table 3. Comparison of Temporal Changes in Epworth Sleepiness Scale (ESS) Scores Between the Intervention and Control Groups at Day 0 and Day 30

Time point	Intervention (n=30) Mean \pm SD	Control (n=30) Mean \pm SD	t	p value†	Cohen's d‡
Day 0	11.80 \pm 3.01	12.57 \pm 2.50	-1.073	0.288	-0.277
Day 30	7.53 \pm 2.30	13.20 \pm 2.47	-9.197	<0.001	-2.375
Wilcoxon Test Value	465	25			
p value	0.000	0.007			
Effect Size	0.876	0.519			

Values are mean \pm SD.

†Between-group comparisons were performed using Welch's t-test.

‡Cohen's d represents the between-group effect size (intervention vs control) at each time point; negative values indicate lower scores in the intervention group.

Table 4. Comparison of Pittsburgh Sleep Quality Index (PSQI) Total Scores Between the Intervention and Control Groups at Day 0 and Day 30

Time point	Intervention (n=30) Mean ± SD	Control (n=30) Mean ± SD	t	p value†	Cohen's d‡
Day 0	13.97 ± 1.38	13.93 ± 1.44	0.092	0.927	0.024
Day 30	7.73 ± 1.86	13.83 ± 1.26	-14.889	<0.001	-3.844
Wilcoxon Test Val	465	135			
p value	0.000	0.787			
Effect Size	0.876	0.002			

Values are mean ± SD.

†Between-group comparisons were performed using Welch's t-test.

‡Cohen's d represents the between-group effect size (intervention vs control) at each time point; negative values indicate lower scores in the intervention group.

Table 5. Comparison of Blessed Orientation-Memory-Concentration Test (BOMCT) Scores Between the Intervention and Control Groups at Day 0 and Day 30

Time point	Intervention (n=30) Mean ± SD	Control (n=30) Mean ± SD	t	p value†	Cohen's d‡
Day 0	12.47 ± 5.07	13.37 ± 5.07	-0.688	0.494	-0.178
Day 30	6.80 ± 3.46	14.47 ± 5.82	-6.205	<0.001	-1.602
Wilcoxon Test Val	351	6.5			
p value	0.000	0.018*			
Effect Size	0.857	0.404			

Values are mean ± SD.

†Between-group comparisons were performed using Welch's t-test.

‡Cohen's d represents the between-group effect size (intervention vs control) at each time point; negative values indicate lower scores in the intervention group.




Figure 1. CONSORT 2025 flow diagram of the study

Figure1.Consort 2025 Flow Chart of the Research

338x190mm (300 x 300 DPI)